Veeco Appoints Shubham Maheshwari as Chief Financial Officer
News May 16, 2014
Veeco Instruments Inc. has appointed Shubham Maheshwari, 42, as its new Executive Vice President, Finance and Chief Financial Officer (CFO). Mr. Maheshwari replaces David D. Glass, who announced his retirement from Veeco last December.
Mr. Maheshwari brings more than 20 years of experience in engineering and finance to Veeco. He most recently served as Chief Financial Officer of OnCore, a global manufacturer of electronic products in the medical, aerospace, defense and industrial markets.
Prior to this role, he held various finance roles including Senior Vice President Finance, Treasury, Tax and Investor Relations at Spansion, a global leader in Flash memory based embedded system solutions. Mr. Maheshwari helped lead Spansion’s emergence from bankruptcy to become a successful public company.
Prior to Spansion, he spent over ten years at KLA-Tencor, a global semiconductor capital equipment manufacturing company, in various senior level corporate development and finance roles, including Vice President of Corporate Development and Corporate Controller. During his tenure at KLA-Tencor, he worked on over $1 billion in acquisition transactions.
He holds a B.S. in Chemical Engineering from the Indian Institute of Technology in Delhi, India, an M.S. in Chemical Engineering from Kansas State University, and an MBA from the Wharton Business School, University of Pennsylvania.
John Peeler, Veeco’s Chairman and Chief Executive Officer, commented, “Shubham brings an ideal mix of highly relevant financial leadership experience to Veeco. I am confident he will hit the ground running to help take Veeco to the next level of performance. I’m extremely pleased that Shubham has joined our leadership team.”
“Veeco is a great match for me and I’m excited to come on board,” commented Mr. Maheshwari. “Veeco has done an impressive job managing through an extended downturn, but I think the best is still in front of the Company. I look forward to helping to strengthen the business and capitalizing on the significant growth opportunities ahead.”
Comments | 0 ADD COMMENT
U.S. FDA Accepts Licence For Biosimilar Trastuzumab
News Jan 12, 2017